Helicobacter pylori eradication therapy in gastric cancer patients who undergo pylorogastrectomy

Helicobacter pylori eradication therapy in gastric cancer patients who undergo pylorogastrectomy - Helicobacter pylori eradication therapy in gastric cancer patients who undergo pylorogastrectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002669

Enrollment

300

Registered

2009-11-01

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer patients who undergo pylorogastrectomy

Interventions

Preoperative Helicobacter pylori eradication triple therapy Postoperative Helicobacter pylori eradication triple therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Gastric cancer patients who undergo pylorogastrectomy

Exclusion criteria

Exclusion criteria: Recurrent gastric cancer,Previous gastric surgery,stage4,underwent total gastrectomy,history of H.pylori eradication therapy,contraindication of H.pylori triple therapy

Design outcomes

Primary

Measure	Time frame
Eradication rate for Helicobacter pylori	—

Secondary

Measure	Time frame
symptoms findings of upper gastrointestinal endoscopy	—

Countries

Japan

Contacts

Public ContactNaoki Hiki

The Cancer Institute Hospital of JFCR Gastroenterological Surgery

03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026